%0 Journal Article
%T BRAF突变的结直肠癌预后及治疗研究进展<br>Advances in Prognosis and Treatment of Colorectal Cancer with BRAF Mutation
%A 陈琪
%A 李瑜英
%J Advances in Clinical Medicine
%P 4565-4570
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.125659
%X 结直肠癌是发病和死亡率较高的肿瘤，大约8%~10%的晚期结肠直肠癌(Colorectal Cancer, CRC)患者出现BRAF改变，特别是V600E突变。并且BRAF突变(BRAF-mt)预后不良与多种因素相关，已被确定为治疗优化的一个重要目标。目前，治疗标准是一种涉及三联化疗和抗EGFR药物的积极策略，但新的治疗方法正在出现。通过查阅国内外相关文献对BRAF突变结直肠癌的预后及治疗研究进展进行综述。<br />
Colorectal cancer is a tumor with high morbidity and mortality, and approximately 8%~10% of pa-tients with advanced colorectal cancer (CRC) have BRAF alterations, especially the V600E mutation. And BRAF mutation (BRAF-mt), with poor prognosis associated with multiple factors, has been identified as an important target for treatment optimization. Currently, the standard of care is an aggressive strategy involving triple chemotherapy and anti-EGFR drugs, but new treatments are emerging. The research progress of prognosis and treatment of BRAF-mutated colorectal cancer was reviewed by reviewing relevant domestic and foreign literatures.
%K 结直肠癌，BRAF突变，预后，免疫治疗<br>Colorectal Cancer
%K BRAF Mutation
%K Prognosis
%K Immunity Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=51761